New hope for tough lymphomas: experimental drug shows promise in Mid-Stage trial

NCT ID NCT04842877

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard-to-treat lymphomas.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • A.Z. Sint Jan AV

    Bruges, 8000, Belgium

  • CH Tourelle Peltzer

    Verviers, 4800, Belgium

  • CH d'Avignon

    Avignon, 84000, France

  • CH de la Côte Basque

    Bayonne, 64109, France

  • CHU Hôtel Dieu

    Nantes, 44093, France

  • CHU Mont-Godinne

    Yvoir, Belgium

  • CHU Pontchaillou

    Rennes, 35003, France

  • CHU d'Estaing

    Clermont-Ferrand, 63000, France

  • CHU de Dijon

    Dijon, 21034, France

  • CHU de Montpellier

    Montpellier, 34295, France

  • Ch Metropole Savoie - Site Chambery

    Chambéry, 73000, France

  • Ch de Bretagne Atlantique -

    Vannes, 56017, France

  • Chd de Vendee

    La Roche-sur-Yon, 85925, France

  • Clinique Victor Hugo

    Le Mans, 72000, France

  • Emmanuel Bachy

    Pierre-Bénite, 69495, France

  • François Lemonnier

    Créteil, 94010, France

  • Gh Region Mulhouse Et Sud Alsace

    Mulhouse, 68070, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Paoli Calmette

    Marseille, 13273, France

  • Institut d'Hématologie de Basse Normandie

    Caen, 14076, France

  • Service des Maladies du Sang - CHRU de Lille

    Lille, 59037, France

  • University Hospital Gent

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.